Juniper Publishers-Cancer Therapy Oncology International Journal

  Cancer Therapy & Oncology International Journal Abstract Multiple myeloma (MM) is a malignant disorder of antibody-producing clonal plasma cells. It is the second most common hematologic neoplasia worldwide [1]. Despite recent advances in myeloma treatment (high-dose chemotherapy followed by autologous stem cell transplantation, novel immunomodulatory drugs, and proteasome inhibitors); MM remains largely incurable with chemotherapy [2]. This is mostly due to the persistence of minimal residual disease (MRD), which leads to high relapse rates [2]. Furthermore, the prognosis of MM patients who become refractory to recently developed novel agents is very poor [1]. Abbreviations: MM: Multiple Myeloma; MRD: Minimal Residual Disease; PD-L1: Programmed Cell Death Ligand; MDSCs: Myeloid-Derived Suppressor Cells; ACT: Adoptive Cellular Therapy; SLAMF7: Signaling Lymphocyte Activating-Molecule Family Member 7; ADCC: Antibody-Dependent Cellular Cytotoxicity;...

  Cancer Therapy & Oncology International Journal    Abstract Prostate cancer within a younger cohort of men continues to be an increasing problem. With a younger population, greater expectations are present, from erectile function, to continence to oncological outcomes. Significant prostate cancer is increasingly diagnosed in younger men, less than 55 years [1]. In a non-screened population young patients are choosing radical surgery for intermediate and high risk disease [1]. This patient group have high expectations with regards to oncological and functional outcomes. The next question arises, what can we do to improve outcomes? Keywords: robotic radical prostatectomy, outcomes Abbreviations: ERSPC: European Randomized Study of Screening for Prostate Cancer; AUA: American Urological Association Mini Review Early-onset prostate cancer (<55 years), dif...

  Cancer Therapy & Oncology International Journal Abstract Neurofibromatosis type 1 (NF1), formerly known as von Recklinghausen’s disease is a nervous system tumor disorder of variable expressivity. Malignant solitary fibrous tumors (SFT) are rare spindle cell soft tissue tumors. We report a case of a 35-year-old male who presented clinically with NF1 and a mass that mimicked a nerve sheath tumor radiologically, but pathologically was, in fact, a malignant solitary fibrous tumor. Based on a literature review, the association between NF1 and malignant SFT has never been published. Keywords: Neurofibromatosis type 1; Malignant solitary fibrous tumor Abbrevations: SFT: Solitary Fibrous Tumors; NF1: Neurofibromatosis type 1 Mini Review Neurofibromatosis type 1 (NF1) is a multisystem disease characterized by cutaneous findings, as well as benign and malignant tumors o...

  Cancer Therapy & Oncology International Journal Abstract Introduction and Objective: This study was aimed to evaluate the QOL among BCS who receiving various treatment strategies in Teaching Hospital, Karapitiya (THK). Method: This cross sectional study was performed with conveniently selected 142 BCS (Mean age (SD) - 55 (10.29) years) at oncology unit of THK during July 2016 using WHOQOL-BREFF questionnaire. Results: Among the studied BCS, 32.4% were studied up to O/L and 61.3% were married. 76.8% were unemployed and 38.7% had monthly income between Rs 10,000-30,000. 51.4% were living with their husband and children and 93% were Buddhist. 34.5% had undergone to CT. Mean (SD) of physical (PD), psychological (PsD), social (SD) and environmental (ED) domains were 47.79 (11.20), 42.17 (15.19), 48.86 (15.68) and 51.83 (13.61) respectively. Age, marital status, level of education and monthly income and current treatments were significantly affect...

  Cancer Therapy & Oncology International Journal Abstract Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms that may affect any portion of the gastrointestinal tract. Surgical resection was previously considered the only treatment modality available, thus prognosis in patients with advanced disease was poor. The emergence of novel therapeutic agents such as imatinib mesylate has altered how physicians now approach and manage these unique malignancies. The addition of these targeted agents has resulted in a significant benefit in median overall survival. Imatinib treatment is generally well tolerated. Side effects such as oedema, rash and gastrointestinal upset may be observed. However respiratory complaints are exceedingly rare. We report a case of imatinib-induced interstitial pneumonitis after five months of treatment in a patient with intermediate risk gastrointestinal stromal tumor of the stomach. Keywords: Imatinib Mesylate; Glivec; Inter...

  Chimeric Antigen Receptor Engineered T (CAR-T) Cells and Cancer Therapy Editorial Gene therapy has demonstrated significant potential as a cancer therapy in the last few years. The greatest successes have been reached by genetic modification of autologous patient T cells with chimeric antigen receptors (CARs), which are novel and synthetic receptors composed of the antigen-binding domain from a B cell receptor fused to the signaling elements associated with a T cell receptor [1]. CAR-T cells are targeted towards malignant cells expressed defined associated antigens. CAR-T cells can overcome the major challenges of immunotherapy such as tolerance to self-antigens and cancer immune system evasion mechanism [2]. Structure of CAR CAR is composed of an extracellular antigen-bindingdomain derived from an antibody (mostly a single-chain fragment of vari...